Latest From Microbiotix Inc.
The time for talking is over when it comes to antimicrobial resistance, says Jim O'Neill, urging the government to 'rediscover the passion for championing' initiatives in the UK, notably the new AMR Centre in Alderley Park near Manchester.
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Microbiotix Inc.
- Senior Management
Terry L Bowlin, PhD, Pres. & CEO
Donald T Moir, PhD, CSO
Richard Gauthier, Head, Bus. Dev.
- Contact Info
Phone: (508) 757-2800
One Innovation Dr.
#3 Biotech Bldg
Worcester, MA 01605
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.